Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell P Fink

Showing results (31-40 of 145) with videos related to

Pageof 15
Sort By:
Current Drug Targets|April 14, 2007
Ethyl pyruvate: a novel treatment for sepsisMitchell P Fink
Critical Care Medicine|July 18, 2009
Sepsis, ghrelin, the cholinergic anti-inflammatory pathway, gut mucosal hyperpermeability, and high-mobility group box 1Mitchell P Fink
Critical Care Medicine|March 20, 2012
Pharmacological effects of inhaled methane: plausible or not?Mitchell P Fink
Critical Care Medicine|August 28, 2013
Recombinant soluble thrombomodulin as an adjunctive treatment for sepsis and disseminated intravascular coagulation: relatively safe and possibly effectiveMitchell P Fink
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|January 7, 2015
Cytopathic hypoxia and sepsis: is mitochondrial dysfunction pathophysiologically important or just an epiphenomenonMitchell P Fink
Critical Care (London, England)|February 13, 2015
Analyzing the value of monitoring duodenal mucosal perfusion using photoplethysmographyMitchell P Fink
Critical Care Medicine|May 20, 2014
Nitric oxide synthase and vascular dysfunction in sepsis: should we target nitric oxide synthase 1, nitric oxide synthase 2, both, or neither?Mitchell P Fink
Trends in Microbiology|November 23, 2006
Promising therapeutic agents for sepsisRajesh Aneja, Mitchell P Fink
Critical Care Medicine|January 16, 2004
Red blood cell physiology in critical illnessMarion Scharte, Mitchell P Fink
Critical Care Clinics|March 23, 2005
Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular levelMitchell P Fink, Russell L Delude
Pageof 15

Showing results (31-40 of 145) with videos related to

Sort By:
Pageof 15
Current Drug Targets|April 14, 2007
Ethyl pyruvate: a novel treatment for sepsisMitchell P Fink
Critical Care Medicine|July 18, 2009
Sepsis, ghrelin, the cholinergic anti-inflammatory pathway, gut mucosal hyperpermeability, and high-mobility group box 1Mitchell P Fink
Critical Care Medicine|March 20, 2012
Pharmacological effects of inhaled methane: plausible or not?Mitchell P Fink
Critical Care Medicine|August 28, 2013
Recombinant soluble thrombomodulin as an adjunctive treatment for sepsis and disseminated intravascular coagulation: relatively safe and possibly effectiveMitchell P Fink
Pediatric Critical Care Medicine : a Journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies|January 7, 2015
Cytopathic hypoxia and sepsis: is mitochondrial dysfunction pathophysiologically important or just an epiphenomenonMitchell P Fink
Critical Care (London, England)|February 13, 2015
Analyzing the value of monitoring duodenal mucosal perfusion using photoplethysmographyMitchell P Fink
Critical Care Medicine|May 20, 2014
Nitric oxide synthase and vascular dysfunction in sepsis: should we target nitric oxide synthase 1, nitric oxide synthase 2, both, or neither?Mitchell P Fink
Trends in Microbiology|November 23, 2006
Promising therapeutic agents for sepsisRajesh Aneja, Mitchell P Fink
Critical Care Medicine|January 16, 2004
Red blood cell physiology in critical illnessMarion Scharte, Mitchell P Fink
Critical Care Clinics|March 23, 2005
Epithelial barrier dysfunction: a unifying theme to explain the pathogenesis of multiple organ dysfunction at the cellular levelMitchell P Fink, Russell L Delude
Pageof 15